Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Invested Capital for the Trailing 12 Months (TTM) ending March 31, 2024: USD 813.42 M

Agios Pharm Invested Capital is USD 813.42 M for the Trailing 12 Months (TTM) ending March 31, 2024, a -82.57% change year over year. Invested capital represents the total amount of capital invested in a company's operations, including both equity and debt. It is calculated by subtracting the sum of current liabilities (excluding short-term debt) from the total assets of a company. Invested capital reflects the long-term financial resources employed in the company's operations. It is an important measure to evaluate a company's capital structure and assess the amount of capital invested in its productive assets.

Agios Pharm Invested Capital for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 4.67 B, a -22.34% change year over year.
Agios Pharm Invested Capital for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 6.01 B, a 21.86% change year over year.
Agios Pharm Invested Capital for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 4.93 B, a 72.67% change year over year.
Agios Pharm Invested Capital for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 2.86 B, a 96.20% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends